The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ε-caprolactone-based nanoparticles

Biomaterials

Volumn 30, Issue 5, 2009, Pages 879-891

  Florindo, H F ^a,b   Pandit, S ^b   Lacerda, L ^b   Goncalves L M D ^a,c   Alpar, H O ^b   Almeida, A J ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

Author keywords

Adjuvants; Nanospheres; Poly caprolactone; Streptococcus equi, Mucosal immunisation

Indexed keywords

ABSORPTION ENHANCERS; ADJUVANTS; ANTIBIOTIC THERAPIES; BACTERIAL INFECTIONS; CAPROLACTONE; CHOLERA TOXIN B SUBUNITS; EMULSION SOLVENTS; IMMUNE RESPONSES; IMMUNOGENICITY; INTRANASAL ADMINISTRATIONS; LYMPH NODES; MUCOADHESIVE POLYMERS; MUCOSAL IMMUNE RESPONSES; STREPTOCOCCUS EQUI, MUCOSAL IMMUNISATION;

AMINES; ANIMALS; ANTIBIOTICS; DRUG PRODUCTS; EMULSIFICATION; EMULSIONS; IMMUNOLOGY; NANOSPHERES; OLEIC ACID; POLYMERS;

ANTIGENS;

ALGINIC ACID; CHITOSAN; CHOLERA TOXIN B SUBUNIT; NANOPARTICLE; NANOSPHERE; OLEIC ACID; POLYCAPROLACTONE; SPERMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS EQUI; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; FEMALE; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYESTERS; POLYMERS; STREPTOCOCCUS EQUI;

ANIMALIA; BACTERIA (MICROORGANISMS); EQUIDAE; MUS; STREPTOCOCCUS EQUI;

EID: 57549114032     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.10.035     Document Type: Article

References (39)

1. Waller A.S., and Jolley K.A. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines. Vet J 173 (2007) 492-501
2. Sweeney C.R., Timoney J.F., Newton J.R., and Hines M.T. Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles. J Vet Intern Med 19 (2005) 123-134
3. Sweeney C.R. Strangles: Streptococcus equi infection in horses. Equine Vet Educ 8 (1996) 317-322
4. Harrington D.J., Sutcliffe I., and Chanter N. The molecular basis of Streptococcus equi infection and disease. Microbes Infect 4 (2002) 501-510
5. Sheoran A.S., Artiushin S., and Timoney J.F. Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin. Vaccine 20 (2002) 1653-1659
6. Amidi M., Romeijn S.G., Verhoef C.J.H.E., Bungener L.H.A., Crommlin D.J.A., and Jiskoot W. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 25 (2007) 144-153
7. Aguilar J.C., and Rodríguez E.G. Vaccine adjuvants revisited. Vaccine 25 (2007) 3752-3762
8. Jaganathan K.S., Rao Y.U., Singh P., Prabakaran D., Gupta S., Jain A., et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 294 (2005) 23-32
9. Almeida A.J., and Alpar H.O. Mucosal immunisation with antigen-containing microparticles. In: Gander B., Merkle H.P., and Corradi G. (Eds). Antigen delivery systems: immunological and technological issues (1997), Harwood Academic Publishers, Amsterdam 207-226
10. Bramwell V.W., and Perrie Y. Particulate delivery systems for vaccines: what can we expect?. J Pharm Pharmacol 58 (2006) 717-728
11. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 19 (2002) 715-728
12. Lemoine D., Deschuyteneer M., Hogge F., and Preat V. Intranasal immunization against influenza virus using polymeric particles. J Biomater Sci Polym Ed 10 (1999) 805-825
13. Partidos C.D. Intranasal vaccines: forthcoming challenges. PSTT 3 (2000) 273-281
14. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
15. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.S., et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 57 (2004) 123-131
16. Borges O., Borchard G., Verhoef jC S.A., and Junginger H.E. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299 (2005) 155-166
17. Sugita Y., Takao K., Toyama Y., and Shirahatal A. Enhancement of intestinal absorption of macromolecules by spermine in rats. Amino Acids 33 (2007) 253-260
18. Ascarateil S., and Dupuis L. Surfactants in vaccine adjuvants: description and perspectives. Vaccine 24S2 (2006) S2/83-S2/85
19. Gogev S., Fays K., Versali M., Gautier S., and Thiry E. Glycol chitosan improves the efficacy of intranasally administered replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpes virus 1. Vaccine 22 (2004) 1946-1953
20. Florindo H.F., Pandit S., Goncalves L.M., Alpar H.O., and Almeida A.J. S. equi antigens adsorbed onto surface modified poly-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 26 (2008) 4168-4177
21. Towbin H., Staehlin T., and Gordin J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
23. Farzad Z., James K., and McClelland D.B.L. Measurement of human and mouse anti-tetanus antibodies and isotype analysis by ELISA. J Immunol Methods 87 (1986) 119-125
24. Ying M., Audran R., Thomasin C., Eberl G., Demotz S., Merkle H.P., et al. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 17 (1999) 1047-1056
25. Baras B., Benoit M.A., and Gillard J. Influence of various technological parameters on the preparation of spray-dried poly(epsilon-caprolactone) microparticles containing a model antigen. J Microencapsul 17 (2000) 485-498
26. Lamprecht A., Ubrich N., Hombreiro P.M., Lehr C., Hoffman M., and Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 184 (1999) 97-105
27. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., and Gilley R.M. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59 (1991) 2978-2986
28. Lee E.S., Park K., Park I.S., and Na K. Glycol chitosan as a stabilizer for protein encapsulated into poly(lactide-co-glycolide) microparticle. Int J Pharm 338 (2007) 310-316
29. Johansen P., Men Y., Merkle H.P., and Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50 (2000) 129-146
30. Benoit M.A., Baras B., and Gillard J. Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery. Int J Pharm 184 (1999) 73-84
31. Singh J., Pandit S., Bramwell V.W., and Alpar H.O. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38 (2006) 96-105
32. Alpar H.O., and Almeida A.J. Identification of some physicochemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery. Eur J Pharm Biopharm 40 (1994) 198-202
33. Isaka M., Yasuda Y., Taniguchi T., et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21 (2003) 1165-1173
34. Azevedo A.F., Galhardas J., Cunha A., Cruz P., Goncalves L.M., and Almeida A.J. Microencapsulation of Streptococcus equi antigens in biodegradable microspheres and preliminary immunisation studies. Eur J Pharm Biopharm 64 2 (2006) 131-137
35. Singh M., Singh A., and Talwar G.P. Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules. Pharm Res 8 (1991) 958-961
36. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 (2001) 21-42
37. Wu H.Y., and Russel M.W. Nasal lymphoid tissue, intranasal immunization and compartmentalization of the common mucosal immune system. Immunol Res 16 (1997) 187-201
38. Eyles J.E., Spiers I.D., Williamson E.D., and Alpar H.O. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal, intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine 16 (1998) 2000-2009
39. Szakal A.K., Burton G.F., Smith J.P., and Tew J.G. Antigen processing and presentation in vivo. In: Spriggs D.R., and Koff W.C. (Eds). Topics in vaccine adjuvant research (2001), CRC Press, Florida 11-21